The standard treatment options in low-and-middle income countries like Ethiopia is usually nothing.
The next best option are cobbled together respiratory devices.
Treatment options that high-income countries can afford are too costly in the low-and-middle-income country context.
The machines for respiratory support are usually built into the walls and the needed infrastructure is not something you will find in low-and-middle income countries.
Side effects for ventilators and including CPAP are cold dry air, they require pressure and their invasiveness induces at-minimum nasal trauma.
We have a have developed a final prototype of a low-cost self-sterilizing humidified high-flow nasal cannula.
Our patented device oxygenates, warms, humidifies, and sterilizes air before it is delivered in a single, compact, and mobile enclosure.
We have secured funding to create 10 more units and we are ready to deploy this in a clinical trial, with a protocol written and hospital partnerships secured in Ethiopia.
Our device has completed bench testing development, piloting, and refinement of clinical materials as well as tested training curriculum with end-users at both Yale and in LMIC settings in like Addis Ababa, Ethiopia.
Feedback from user testing in Addis Ababa influenced the design of the device and ranged from refined circuit architecture to considerations for a more efficient heating system that were integrated into the device, as a result of the analysis of data from device testing.
There is a sizable global market for these devices, recent exits have been favorable, and it is not only cheaper to develop this overseas but better as that in-country input is critical to being successful.